Blog
RSS FeedPosted by Michael Wonder on 20 Feb 2020
ICER releases draft evidence report on therapies for cystic fibrosis
20 February 2020 - Public comment period now open until 18 March 2020; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 12 Feb 2020
ICER methods could be illegal in US, claims US think tank
11 February 2020 - The method used by the US Institute for Clinical and Economic Review (ICER) to gauge whether ...
Posted by Michael Wonder on 02 Feb 2020
ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework
31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...
Posted by Michael Wonder on 25 Jan 2020
ICER posts draft scoping document for the assessment of treatments for haemophilia A
24 January 2020 - Document open to public comment until 13 February 2020. ...
Posted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
Posted by Michael Wonder on 10 Jan 2020
ICER releases evidence report on acute treatments for migraine
10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...
Posted by Michael Wonder on 09 Jan 2020
ICER issues final report and policy recommendations on JAK inhibitors for rheumatoid arthritis
9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on ...
Posted by Michael Wonder on 06 Jan 2020
ICER posts draft scoping document for the assessment of treatments for beta thalassaemia
6 January 2020 - Document open to public comment until 27 January 2020. ...
Posted by Michael Wonder on 11 Dec 2019
Expanding use of multi-criteria decision analysis for health technology assessment
11 December 2019 - As America’s health care system continues to evolve, it is critical that our perception of care ...
Posted by Michael Wonder on 09 Dec 2019
ICER issues final report and policy recommendations for add-on therapies to treat type 2 diabetes
9 December 2019 - Oral GLP-1 semaglutide achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than SGLT-2 competitor empagliflozin. ...
Posted by Michael Wonder on 03 Dec 2019
Does the Institute for Clinical and Economic Review revise its findings in response to industry comments?
2 December 2019 - The ICER has gained prominence through its work conducting health technology assessments of pharmaceuticals in the United ...
Posted by Michael Wonder on 13 Nov 2019
ICER finalises method adaptations for assessing potential cures and other high-impact single or short-term therapies
12 November 2019 - Collaborative project with NICE and CADTH leads to important adaptations for ICER’s methods including creation of optimistic ...
Posted by Michael Wonder on 07 Nov 2019
ICER releases draft evidence report on acute migraine therapies
7 November 2019 - Public comment period on preliminary draft now open until 6 December 2019; requests to make oral comment ...
Posted by Michael Wonder on 05 Nov 2019
Obscure model puts a price on good health—and drives down drug costs
4 November 2109 - Concept called QALY places dollar value on the health medicines can restore; ‘starting to influence decision-making’. ...
Posted by Michael Wonder on 01 Nov 2019
ICER report finds oral GLP-1 semaglutide, at estimated net price, less cost-effective than SGLT-2 competitor empagliflozin as add-on therapy for type 2 diabetes
1 November 2019 - Semaglutide as add-on therapy to metformin achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than ...